Dynavax (DVAX) Q2 Revenue Jumps 29%

Dynavax Technologies (DVAX) significantly surpassed Q2 2025 analyst expectations, reporting GAAP revenue of $95.4 million and diluted EPS of $0.14, largely driven by record sales of its HEPLISAV-B hepatitis B vaccine, which generated $91.9 million in net product revenue. The company raised its full-year 2025 HEPLISAV-B net product revenue guidance to $315-$325 million, reflecting sustained demand and market share gains for the vaccine. Additionally, Dynavax made progress on its clinical pipeline, with a key shingles vaccine candidate data readout expected in August 2025, underscoring confidence in its growth trajectory.

Analysis

Dynavax Technologies delivered a robust second quarter for 2025, significantly outperforming analyst expectations with GAAP revenue of $95.4 million versus an $86.7 million estimate, and a GAAP diluted EPS of $0.14, beating the $0.11 consensus. This performance represents substantial year-over-year growth of 29.3% in revenue and 75% in EPS, primarily fueled by record net product revenue of $91.9 million from its flagship hepatitis B vaccine, HEPLISAV-B. The vaccine's commercial momentum is tangible, with its U.S. market share expanding to approximately 45%, driven by adoption in the retail pharmacy channel and favorable CDC universal vaccination recommendations. Management's confidence is underscored by the decision to raise the lower end of its full-year 2025 HEPLISAV-B revenue guidance to a range of $315–$325 million. While the core business thrives with projected gross margins around 80%, the company is also investing heavily in its future. A key near-term catalyst is the upcoming top-line data readout in August 2025 for its Z-1018 shingles vaccine candidate. However, this growth investment is reflected in rising operating expenses, with R&D up 10.7% and SG&A up 20.9% year-over-year. The company maintains a healthy cash position of $613.7 million, though this is down from $713.8 million at year-end 2024, partly due to the completion of a $200 million share repurchase program.

Key Decisions for Investors

• The strong HEPLISAV-B performance and raised revenue guidance validate the core commercial strategy, reinforcing the near-term investment case based on continued market share gains in the adult hepatitis B vaccine market.
• The imminent top-line data readout for the Z-1018 shingles vaccine in August 2025 is a critical near-term catalyst that could significantly de-risk the pipeline and unlock value beyond the company's current flagship product.
• While revenue growth is strong, it is prudent to monitor rising R&D and SG&A expenses and the corresponding decrease in cash reserves to ensure the company effectively balances investment in its pipeline with maintaining its robust profitability.